U.S. purchases PEPFAR doses and Gilead sells drugs at no profit following Trump administration's foreign aid cuts.
2 reports, 2 independent
Updated Sep 5
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
U.S. purchases PEPFAR doses and Gilead sells drugs at no profit following Trump administration's foreign aid cuts.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Trump administration cuts to foreign aid lead to PEPFAR purchases and Gilead selling drugs at no profit.1 source
Gilead partners with PEPFAR to deliver lenacapavir, supported by the America First agenda.1 source
Keep exploring
The entities involved
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
Related events
Coverage
Newest first; wire copies grouped- Associated Press FinanceThe US will buy 2 million doses of an HIV prevention drug for low-income countries WASHINGTON (AP) — The U.S. is purchasing enough doses of a new twice-a-year HIV prevention shot to share with up to
- Business WireGilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries – PEPFAR, Coordinated